Skip to main content

Table 2 Baseline clinical characteristics for patients in the ReACCh-Out and the Nordic JIA cohort according to severe disease course or non-severe disease course

From: Validation of prediction models of severe disease course and non-achievement of remission in juvenile idiopathic arthritis: part 1—results of the Canadian model in the Nordic cohort

CharacteristicsReACCh-Out development cohortNordic validation cohort
Severe disease (n = 125)Non-severe (n = 484)Severe disease (n = 98)Non-severe (n = 342)
Age at onset, years9.9 (5.4–12.0), n = 1236.9 (2.5–10.7), n = 4748.1 (2.9–11.0)5.2 (2.3–9.0)
Female, n (%)88 (70.4)325 (67.1)78 (79.6)213 (62.3)
Disease onset to diagnosis, months5.6 (2.4–13.9)3.3 (1.6–6.4)2.4 (1.4–5.1), n = 941.4 (1.4–2.8), n = 321
Disease onset to enrollment, months8.8 (4.9–17.0)5.5 (2.8–9.9)6.0 (6.0–9.0)7.0 (6.0–8.0)
JIA category, n (%)
 Oligoarthritis9 (7.2)214 (44.2)27 (27.6)200 (58.5)
 RF-neg. polyarthritis44 (35.2)85 (17.6)37 (37.8)57 (16.7)
 RF-pos. polyarthritis20 (16.0)6 (1.2)3 (3.1)1 (0.3)
 Systemic10 (8.0)37 (7.6)2 (2.0)15 (4.4)
 Enthesitis-related24 (19.2)57 (11.8)9 (9.2)25 (7.3)
 Psoriatic4 (3.2)32 (6.6)1 (1.0)5 (1.5)
 Undifferentiated14 (11.2)53 (11.0)19 (19.4)39 (11.4)
Active joints, n (%)
 Cervical arthritis21 (16.8)8 (1.7)22 (22.7)16 (4.7)
 Finger arthritis86 (68.8)122 (25.2)63 (65.0)72 (21.1)
 Ankle arthritis78 (62.4)140 (28.9)61 (62.9)137 (40.1)
 Hip arthritis35 (28.0)34 (7.0)19 (19.6)45 (13.2)
 Cumulative active joint counta13 (4–26)2 (1–4)9 (5–14)2 (1–5)
 Physician global assessment VAS5.3 (3.2–7.2)2.3 (1.0–4.6)2.4 (1.0–4.7), n = 751.0 (0.3–2.1), n = 173
 Parents’ global assessment VAS3.6 (1.8–5.7), n = 1141.3 (0.3–3.5), n = 4402.3 (1.0–5.0), n = 760.9 (0.0–2.5), n = 195
 Pain VAS5.0 (2.7–6.8), n = 1142.0 (0.5–5.0), n = 4403.4 (1.1–5.0), n = 750.8 (0.0–2.8), n = 192
 CHAQ0.9 (0.3–1.4), n = 1090.3 (0.0–0.8), n = 4080.9 (0.3–1.4), n = 780.1 (0.0–0.7), n = 200
 Morning stiffness, n (%)102/124 (82.3)b334/447 (74.7)b60/86 (69.8)c60/254 (23.6)c
 ESR mm/hour20 (9–45), n = 11920 (9–36), n = 43316 (8–39), n = 7714 (8–25), n = 281
 CRP mg/l5.8 (0.4–34.0), n = 982.0 (0.1–10.0), n = 3710.0 (0.0–22.5), n = 800.0 (0.0–10.0), n = 274
 ANA positive, n (%)54 (43.0)d233 (48.0)d22/95 (23.2)93/332 (28.3)
 RF positive, n (%)24 (19.2)d21 (4.3)d4/70 (5.7)6/171 (3.5)
 HLA B27 positive, n (%)18 (14.4)d46 (9.5)d23/96 (24.0)63/314 (20.1)
Treatment by first study visit, n (%)
 NSAIDs115/125 (92.0)451/484 (93.2)83/97 (85.6)290/337 (86.1)
 Joint injections9/125 (7.2)92/484 (19.0)46/95 (48.4)195/334 (58.4)
 DMARDs89/125 (71.2)114/484 (23.6)39/94 (41.5)53/320 (16.6)
 Biologics2/125 (1.6)000
  1. Numbers are median interquartile range (IQR) unless otherwise specified
  2. VAS visual analogue scale, CHAQ Childhood Health Assessment Questionnaire, ESR erythrocyte sedimentation rate, CRP C-reactive protein, ANA antinuclear antibodies, RF rheumatoid factor, HLA B27 Human Leucocyte Antigen B27, NSAID non-steroidal anti-inflammatory drug, DMARD disease modifying antirheumatic drug
  3. aThe Nordic cohort used the cumulative joint count within 6 months of disease onset, and the ReACCh-Out cohort used the active joint count at baseline
  4. bMorning stiffness > 30 min
  5. cMorning stiffness > 15 min
  6. dValues on ANA, RF, and HLA B7 for the Canadian cohort are after imputation